Emergent BioSolutions Inc. (EBS) Financials

EBS Assets vs Liabilities
DateAssetsLiabilities
March 31, 2026 1.3 billion 797.3 million
Dec. 31, 2025 1.3 billion 796.0 million
Sept. 30, 2025 1.5 billion 878.5 million
June 30, 2025 1.4 billion 880.9 million

EBS Free Cash Flow and Stock based compensation
Graph available only for paid members. Upgrade to see it.
DateFree Cash FlowStock based compensation
March 31, 2026 -36.2 million 1.9 million
Dec. 31, 2025 73.8 million 5.3 million
Sept. 30, 2025 -5.7 million 4.8 million
June 30, 2025 103.5 million 4.6 million

EBS Net Income
Graph available only for paid members. Upgrade to see it.
DateNet Income
March 31, 2026 6.8 million
Dec. 31, 2025 -54.6 million
Sept. 30, 2025 51.2 million
June 30, 2025 -12.0 million

EBS Cash and Debt
Graph available only for paid members. Upgrade to see it.
DateCashDebtCapital Lease
March 31, 2026 160.3 million 573.6 million -
Dec. 31, 2025 205.4 million 572.1 million -
Sept. 30, 2025 245.5 million 663.1 million -
June 30, 2025 271.0 million 667.8 million 6.5 million

EBS Shares Outstanding
Graph available only for paid members. Upgrade to see it.
DateShares Outstanding
March 31, 2026 56.5 million
Dec. 31, 2025 52.4 million
Sept. 30, 2025 56.5 million
June 30, 2025 54.2 million

EBS Expenses
Graph available only for paid members. Upgrade to see it.
DateCapexR&DG&AS&M
March 31, 2026 2.4 million 10.5 million 46.6 million -
Dec. 31, 2025 3.9 million 12.1 million 51.1 million -
Sept. 30, 2025 3.4 million 13.5 million 38.8 million -
June 30, 2025 2.9 million 13.0 million 44.0 million -

EBS Cost of Revenue
Graph available only for paid members. Upgrade to see it.
DateRevenueCost of Revenue
March 31, 2026 156.1 million 88.5 million
Dec. 31, 2025 148.7 million 102.1 million
Sept. 30, 2025 231.1 million 102.0 million
June 30, 2025 140.9 million 83.4 million

EBS Revenue by Segment
Graph available only for paid members. Upgrade to see it.

EBS

Price: $8.07

52 week price:
5.62
14.06

Earnings Per Share: -0.19 USD

Exchange: NYQ

Sector: Healthcare

Industry: Drug Manufacturers - Specialty & Generic

Country: United States

Volume: 633400

Ebitda: 58.1 million

Market Capitalization: 423.3 million

Links: